Bernhard Babel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Avextra AG, a European pharmaceutical company that specialises in cannabis-based medicines, has closed its most recent capital raise, securing over €20m ($21.5m) in investment. The German firm plans to use the funding to expand its distribution channels across Europe and to accelerate clinical trials to develop new treatment options for specific health conditions. Avextra also aims to enhance the market development of its product portfolio in Germany. The capital raise was supported by existing investors, strategic partners and new institutional investors. The funding will help the company t...

Avextra announces the closing of its most recent funding round at a valuation of EUR 100 million, concluding a significant raise over the last 18 ...

Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim of designing

European vertically-integrated manufacturer of cannabis-based medicines Avextra AG unveiled the Avextra Alliance for Evidence-based Cannabis Medicine on Wednesday

Seed Innovations Ltd on Monday said it sold most of its interest in Avextra AG, formerly known as Eurox Group, for around EUR2.9 million. Shares in Seeds Innovations were up 8.8% to 2.61 pence each...